Yue Yu

Yue Yu

Auto-generated profile, based on publicly available information

Yue Yu

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
YYYue Yu
Yue Yu
RSRuixue Shuai
Ruixue Shuai
LLLili Liang
Lili Liang
WQWenjuan Qiu
Wenjuan Qiu
LSLinghua Shen
Linghua Shen
LHLianshu Han
Lianshu Han
Background: To summarize the relationship between different MMUT gene mutations and the response to vitamin B12 in MMA.Methods: This was a retrospective study of patients diagnosed with mut‐type MMA. All patients with mut‐type MMA were tested for responsiveness to vitamin B12.Results: There were 81, 27, and 158 patients in the completely responsive, partially responsive, and nonresponsive groups, respectively, and the proportions of symptom occurrence were 30/81 (37.0%), 21/27 (77.8%), and 131/158 (82.9%), respectively (p < .001). The median levels of posttreatment propionyl carnitine (C3), C3/acetyl carnitine (C2) ratio in the blood, and methylmalonic acid in the urine were all lower than pretreatment, and the median level of C3/C2 ratio in the completely responsive group was within the normal range. In 266 patients, 144 different mutations in the MMUT gene were identified. Patients with the mutations of c.1663G>A, c.2080C>T, c.1880A>G, c.1208G>A, etc. were completely responsive and with the mutations of c.1741C>T, c.1630_1631GG>TA, c.599T>C, etc. were partially responsive. The proportions of healthy/developmental delay outcomes in the three groups were 63.0%/23.5%, 33.3%/40.7%, and 13.3%/60.1%, respectively (p < .001).Conclusion: Different mutations in the MMUT gene are associated with the effect of vitamin B12 treatment.

9 December 2021 in BMJ Surgery, Interventions, & Health Technologies
Verified
Journal Article
Open access
PDF file
SDSanket S Dhruva
Sanket S Dhruva
GJGuoqian Jiang
Guoqian Jiang
ADAmit A Doshi
Amit A Doshi
DFDaniel J Friedman
Daniel J Friedman
EBEric Brandt
Eric Brandt
JDJr. Joseph P Drozda
Jr. Joseph P Drozda
Objectives To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia. Design Retrospective cohort. Setting Three health systems in the USA. Participants Patients receiving ablation with the two ablation catheters of interest at any of the three health systems. Main outcome measures Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians. Results Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation. Conclusions It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.